M Ventures is the strategic, corporate venture capital arm of Merck that invests globally in transformational ideas and innovative entrepreneurs.
Portfolio
2
companies
Lightcast Discovery
Lightcast Discovery builds a novel single-cell functional analysis platform for life science research.
NRG Therapeutics
NRG Therapeutics develops mitochondrial-targeted treatments for neurodegenerative conditions.
Christian Uhrich
Principal
Christian brings biotechnology investment experience from his role as an executive investment director and principal at M Ventures. He also serves on the boards of several therapeutics and life sciences companies.
LinkedInThe financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
"Developing new drugs to treat neurological diseases is very challenging, but is receiving increased interest given the high unmet medical need and growing prevalence in ageing populations."
M Ventures led the Series B round to support the company ahead of its commercial launch.
"The power of single-cell analysis to uncover the complexities of biology has become increasingly evident, but much of the work still focuses on the transcriptome as the primary readout."
